BBA
CBAY

Baker Bros. Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Baker Bros. Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,170,464
Closed -$13.6M – 114
2022
Q4 		$13.6M Hold
2,170,464
– – 0.08% 51
2022
Q3 		$7.6M Hold
2,170,464
– – 0.05% 67
2022
Q2 		$6.4M Hold
2,170,464
– – 0.04% 73
2022
Q1 		$6.75M Hold
2,170,464
– – 0.04% 79
2021
Q4 		$7.34M Hold
2,170,464
– – 0.04% 84
2021
Q3 		$7.92M Hold
2,170,464
– – 0.03% 83
2021
Q2 		$9.46M Hold
2,170,464
– – 0.04% 77
2021
Q1 		$9.85M Sell
2,170,464
-722,812
-25% -$3.89M 0.04% 75
2020
Q4 		$16.6M Sell
2,893,276
-359,266
-11% -$2.72M 0.06% 61
2020
Q3 		$23.5M Buy
3,252,542
+1,729,750
+114% +$9.25M 0.09% 49
2020
Q2 		$5.32M Buy
+1,522,792
New +$4.39M 0.02% 79
2019
Q4 		– Sell
-5,707,411
Closed -$29.2M – 106
2019
Q3 		$29.2M Hold
5,707,411
– – 0.2% 36
2019
Q2 		$40.9M Hold
5,707,411
– – 0.28% 33
2019
Q1 		$75.8M Buy
5,707,411
+789,711
+16% +$8.4M 0.49% 20
2018
Q4 		$38.7M Hold
4,917,700
– – 0.32% 27
2018
Q3 		$54.5M Hold
4,917,700
– – 0.36% 25
2018
Q2 		$66M Buy
4,917,700
+1,000,000
+26% +$12.5M 0.5% 22
2018
Q1 		$50.9M Buy
3,917,700
+925,925
+31% +$11.5M 0.43% 27
2017
Q4 		$27.5M Hold
2,991,775
– – 0.24% 38
2017
Q3 		$24.1M Buy
2,991,775
+1,700,000
+132% +$11.5M 0.2% 34
2017
Q2 		$7.44M Sell
1,291,775
-121,724
-9% -$518K 0.07% 55
2017
Q1 		$6.08M Buy
1,413,499
+1,104,231
+357% +$3.17M 0.05% 61
2016
Q4 		$535K Buy
+309,268
New +$546K 0.01% 119

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Bros. Advisors's CBAY Position: Q1 2023 in Review

Baker Bros. Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 2,170,464 shares — an estimated $13.6M sold.

Baker Bros. Advisors first reported a position in CBAY in Q4 2016 and held it in 23 quarters. The position peaked at $75.8M in Q1 2019. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

  • Baker Bros. Advisors reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,170,464 Cymabay Therapeutics shares in Q1 2023, an estimated $13.6M.
  • Baker Bros. Advisors first reported a position in Cymabay Therapeutics in Q4 2016 and held it in 23 quarters.
  • Baker Bros. Advisors's Cymabay Therapeutics position peaked at $75.8M in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.